ALS shares surged more than 25 per cent after the testing, inspection and certification group rebuffed a $2.7 billion takeover bid from two private equity firms, setting the scene for a potential bidding war.
ALS shares surged more than 25 per cent after the testing, inspection and certification group rebuffed a $2.7 billion takeover bid from two private equity firms, setting the scene for a potential bidding war.